Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Author： Chang Susan   Wen Patrick   Cloughesy Timothy   Greenberg Harry   Schiff David   Conrad Charles   Fink Karen   Robins H.   Angelis Lisa   Raizer Jeffrey   Hess Kenneth   Aldape Ken   Lamborn Kathleen   Kuhn John   Dancey Janet   Prados Michael  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.4, 2005-08, pp. : 357-361

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme

By Mikkelsen Tom   Lush Richard   Grossman Stuart   Carson Kathryn   Fisher Joy   Alavi Jane   Rosenfeld Steve  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 259-263

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

By Jakobsen Jan Nyrop   Hasselbalch Benedikte   Stockhausen Marie-Thééréése   Lassen Ulrik   Poulsen Hans Skovgaard  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 825-833

Informa Healthcare

Access to resources Recommend Favorite

Temsirolimus: CCI 779, CCI-779, Cell Cycle Inhibitor-779

By Adis International Limited  

Drugs in R&D, Vol. 5, Iss. 6, 2004-01 ,pp. : 363-367

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Temozolomide in the Treatment of Recurrent Glioblastoma Multiforme

By Martikainen Janne A.  

PharmacoEconomics, Vol. 23, Iss. 8, 2005-01 ,pp. : 803-815

Adis International

Access to resources Recommend Favorite

CCI 779 active in refractory metastatic renal cancer

By  

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite